Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline

Garbe, Claus; Peris, Ketty; Hauschild, Axel; Saïag, Philippe; Middleton, Mark R.; Spatz, Alan; Grob, Jean-Jacques; Malvehy, Josep; Newton-Bishop, Julia; Stratigos, Alexander; Pehamberger, Hubert; Eggermont, Alexander

doi:10.1016/j.ejca.2009.10.032

Cited by 285 publications

(214 citation statements)

References 109 publications

Supporting

Mentioning

191

Contrasting

Unclassified

Order By: Relevance

“…Usually resistant to both chemotherapy and radiotherapy, metastatic melanoma represents the most lethal form of skin cancer. Indeed, even though primary melanoma is successfully treated in most cases by surgical excision, prognosis becomes unfavorable in the metastatic phase, lowering survival to 20% to 40% at 10 years in patients with clinically apparent regional lymph node metastases (2). Thus, effective alternative therapeutic approaches for the treatment of melanoma are eagerly required.…”

Section: Introductionmentioning

confidence: 99%

Long Pentraxin-3 Inhibits Epithelial–Mesenchymal Transition in Melanoma Cells

Ronca

Salle

Giacomini

et al. 2013

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

During melanoma progression, malignant melanocytes are reprogrammed into mesenchymal-like cells through to an epithelial-mesenchymal transition (EMT) process associated with the acquisition of an invasive, prometastatic phenotype. The fibroblast growth factor-2 (FGF2)/FGF receptor (FGFR) system plays a pivotal role in melanoma, leading to autocrine/paracrine induction of tumor cell proliferation and angiogenesis. Long pentraxin-3 (PTX3) interacts with FGF2, and other FGF family members, inhibiting FGF-dependent neovascularization and tumor growth. Here, PTX3 protein and the PTX3-derived acetylated pentapeptide Ac-ARPCA-NH 2 inhibit FGF2-driven proliferation and downstream FGFR signaling in murine melanoma B16-F10 cells. Moreover, human PTX3-overexpressing hPTX_B16-F10 cells are characterized by the reversed transition from a mesenchymal to an epithelial-like appearance, inhibition of cell proliferation, loss of clonogenic potential, reduced motility and invasive capacity, downregulation of various mesenchymal markers, and upregulation of the epithelial marker E-cadherin. Accordingly, PTX3 affects cell proliferation and EMT transition in human A375 and A2058 melanoma cells. Also, hPTX_B16-F10 cells showed a reduced tumorigenic and metastatic activity in syngeneic C57BL/6 mice. In conclusion, PTX3 inhibits FGF/FGFR-driven EMT in melanoma cells, hampering their tumorigenic and metastatic potential. These data represent the first experimental evidence about a nonredundant role of the FGF/FGFR system in the modulation of the EMT process in melanoma and indicate that PTX3 or its derivatives may represent the basis for the design of novel therapeutic approaches in FGF/FGFRdependent tumors, including melanoma. Mol Cancer Ther; 12(12); 2760-71. Ó2013 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

Long Pentraxin-3 Inhibits Epithelial–Mesenchymal Transition in Melanoma Cells

Ronca

Salle

Giacomini

et al. 2013

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…Melanoma represents only a small proportion of all skin cancer cases (<5%) (3), but is responsible for approximately 90% of skin cancer-related deaths (4). Although melanoma affects people of all ages, 34% of patients are younger than 55 years old at diagnosis (5).…”

Section: Introductionmentioning

confidence: 99%

Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States

Chen

Hines

et al. 2017

Journal of Dermatological Treatment

View full text Add to dashboard Cite

“…Another method that may be helpful in distinguishing between nevi and melanoma is fluorescence in-situ hybridization (FISH) Morey et al,et al, 2009]. In general, for a clinically node negative patient with a primary lesion that is thicker than 1 mm -particularly in the 1 -4 mm range -consideration should be given to performing a sentinel lymph node biopsy (SLNB) [Garbe et al, 2010;Testori et al, 2009]. The value of SLNB in patients with melanomas less than 1 mm (T1; "thin") or greater than 4 mm (T4; "thick") in thickness remains less well defined.…”

Section: Surgical Management Of Melanocytic Lesions Of Uncertain Malimentioning

confidence: 99%